| ID Source | ID |
|---|---|
| PubMed CID | 641240 |
| CHEMBL ID | 1455983 |
| SCHEMBL ID | 702309 |
| MeSH ID | M0042492 |
| Synonym |
|---|
| smr001224537 |
| MLS002152945 |
| nsc-76595 |
| 3234-02-4 |
| 2-butene-1, 2,3-dibromo- |
| nsc76595 |
| inchi=1/c4h6br2o2/c5-3(1-7)4(6)2-8/h7-8h,1-2h2/b4-3 |
| (2e)-2,3-dibromobut-2-ene-1,4-diol |
| 2-butene-1,4-diol, 2,3-dibromo-, (2e)- |
| 2,3-dibromo-2-butene-1,4-diol |
| NCGC00091740-01 |
| ccris 4781 |
| einecs 221-779-5 |
| ai3-26932 |
| 2,3-dibromobutene-1,4-diol |
| nsc 76595 |
| 2-butene-1,4-diol, 2,3-dibromo- |
| trans-2,3-dibromo-2-butene-1,4-diol, 97% |
| trans-2,3-dibromo-2-butene-1,4-diol , |
| (e)-2,3-dibromobut-2-ene-1,4-diol |
| AKOS003368867 |
| trans-2,3-dibromo-1,4-dihydroxy-2-butene |
| D2169 |
| 21285-46-1 |
| NCGC00091740-02 |
| HMS3039O16 |
| unii-9jdk8xu90x |
| 9jdk8xu90x , |
| NCGC00258653-01 |
| (2e)-2,3-dibromo-2-butene-1,4-diol |
| dtxsid3024942 , |
| dtxcid10196620 |
| tox21_201101 |
| cas-21285-46-1 |
| einecs 244-313-2 |
| (e)-2,3-dibromo-2-butene-1,4-diol |
| w297831a99 , |
| unii-w297831a99 |
| 2,3-dibromo-2-butene-1,4-diol, (e)- |
| SCHEMBL702309 |
| W-106846 |
| CHEMBL1455983 |
| 2-butene-1,4-diol, 2,3-dibromo-, (e)- |
| (2e)-2,3-dibromo-2-butene-1,4-diol # |
| 2,3-dibromo-2-butene-1,4-diol, trans- |
| trans-1,4-dihydroxy-2,3-dibromo-2-butene |
| 2-butene-1,4-diol,2,3-dibromo-,(2e)- |
| AS-12280 |
| H12068 |
| Q27292221 |
| EN300-7394011 |
| A923639 |
| CS-0137360 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 44.6684 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| AR protein | Homo sapiens (human) | Potency | 48.1630 | 0.0002 | 21.2231 | 8,912.5098 | AID743054 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 25.1189 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.1259 | 0.0002 | 14.3764 | 60.0339 | AID588532 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 68.0320 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 68.0320 | 0.0002 | 29.3054 | 16,493.5996 | AID743080 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 60.6336 | 0.0007 | 23.0674 | 1,258.9301 | AID743122 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 2.7084 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 74.9780 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 39.8107 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 2.0596 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 48.1630 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||